Author: Editor

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether there are emerging mutations in FLT3 mutated relapsed/refractory acute myeloid leukemia (AML) that respond to gilteritinib.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine, @UCSFCancer on whether all acute myeloid leukemia (AML) patients should be tested for FLT3.

Catherine Smith, MD, Assistant Professor, Division of Hematology/Oncology, Department of Medicine @UCSFMedicine tells us about the outcomes of the Phase 3 ADMIRAL trial and why it is important to the management of acute myeloid leukemia.

Two-drug combination effective in lab studies against aggressive prostate tumors Research team identifies new approach to treating prostate cancer Metabolic targeting effective in lab study against aggressive prostate tumors Combining new, traditional approaches may prevent cancer recurrence A Roswell Park Comprehensive Cancer Center research team has identified a novel combination therapy that demonstrates a new approach to treating prostate cancer, reporting their findings in the journal Nature Communications. This new therapeutic strategy is the first to target metabolic processes uniquely important to prostate cancer — specifically, two enzymes in the connected polyamine catabolic pathway and the methionine salvage pathway.  Dr. Dominick Smiraglia and team…

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, elaborates on outcomes from the Phase 2 CAPTIVATE study investigating the BTK inhibitor ibrutinib plus venetoclax in the 1st line treatment of chronic lymphocytic lymphoma (CLL).

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, considers whether recent clinical data supports the use of CAR-T cell therapy in the management of lymphomas.

Tanya Siddiqi, MD, Director, CLL Program, Toni Stephenson Lymphoma Center, Associate Clinical Professor, Department of Hematology, City of Hope, offers impressions of the Transcend-NHL data investigating the use of CAR-T cell therapy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, considers whether minimal residual disease (MRD) is a valid endpoint when measuring treatment efficacy in chronic lymphocytic leukemia (CLL).

John Seymour, MBBS, PhD, Professor, Director of the Department of Hematology, Peter MacCallum Cancer Centre, Melbourne Australia, tells us about the four-year update on the outcomes of the MURANO study, investigating venetoclax plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (CLL).

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, on whether medical oncologists are adopting therapeutic biosimilars in treatment algorithms.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, offers opinion on the most promising studies in multiple myeloma (MM) presented at ASH 2019.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, regarding the role of proteasome inhibitors in maintenance therapy for multiple myeloma patients.

Robert Rifkin, MD, FACP, Attending Physician, Department of Cellular Therapy, Presbyterian/St. Luke’s Medical Center, explains the role of daratumumab as a maintenance therapy in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer discusses the data investigating iberdomide presented at ASH 2019.

Adult cancer patients reported better physical and social function after undergoing CAR-T therapy Adult lymphoma patients whose disease was effectively treated with chimeric antigen receptor T-cell (CAR-T) therapy showed marked improvement on a variety of self-reported quality of life measures, according to a study published today in Blood Advances. The study offers evidence that CAR-T may not only extend cancer patients’ survival, but also improve their quality of life after treatment.Prior to the advent of CAR-T and other forms of cellular immunotherapy, patients with diffuse large B-cell lymphoma (DLBCL) had limited treatment options, and patients with advanced DLBCL had often already exhausted those…

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer provides opinion on the role of BCMA CAR-T cells in the management of multiple myeloma (MM).

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer considers the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients.

Joshua Richter, MD, Assistant Professor, Division of Hematology and Medical Oncology @TischCancer tells us about the design and outcomes of the Phase 3 CANDOR study in relapsed/refractory multiple myeloma.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope considers whether there is sufficient evidence to use bridging therapy before CAR-T therapy.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope discusses clinical evidence supporting the use of CAR-T cell therapies in the treatment of aggressive B-cell lymphomas.

Leslie Popplewell, MD, Associate Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, Toni Stephenson Lymphoma Center-City of Hope shares her thoughts on the role of CAR-T cell therapy in the treatment of aggressive B-cell lymphomas.

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced the final data from its CTCL clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma (CTCL), which was published and presented by Dr. M. Sokolowska-Wojdylo in conjunction with the 4th Annual World Congress of Cutaneous Lymphomas in Barcelona, Spain on February 13, 2020.  The final results supported the safety of topical WP1220 and demonstrated a median improvement in the Composite Assessment of Index Lesion Severity (CAILS) score of 56% in treated (index) lesions for patients completing the…

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses prognostic factors in acute myeloid leukemia (AML) patients.

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML).

Daniel Pollyea, MD, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms.

Jae H. Park, MD, Associate, Leukemia Service, Department of Medicine, @sloan_kettering shares clinical outcomes from the investigation of the vemurafenib combined with obinutuzumab in patients with hairy cell leukemia.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, tells us about the collaboration between the Leukemia and Lymphoma Society and the American Society of Hematology.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, elaborates on what the leukemia and lymphoma society is doing to help educate their membership on the novel agents and approaches.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, offers opinion on the most exciting progress being made in the treatment of lymphoma, leukemia and multiple myeloma.

Gwen Nichols, MD, Chief Medical Officer-Physician, Scientific Research Portfolio, Patient Access Services, Policy and Advocacy Initiatives, Leukemia and Lymphoma Society, provides opinion on the most promising clinical presentations from ASH 2019.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, tells us about the results of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL).

In a new Cleveland Clinic-led study published in JAMA Oncology, researchers show that a testosterone-related genetic variant – HSD3B1(1245C) – is associated with more aggressive disease and shorter survival in men with metastatic prostate cancer.   This study – the first clinical trial validation of the relationship between HSD3B1 status and clinical outcomes – suggests that genetic testing for HSD3B1(1245C) may help physicians identify patients most likely to benefit from additional and more aggressive treatment.   Nima Sharifi, M.D., of Cleveland Clinic’s Lerner Research Institute, and colleagues retrospectively analyzed data from 475 participants enrolled in a large, multi-center national clinical trial testing the efficacy of androgen deprivation…

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers whether off-the-shelf CAR-T cell therapy is becoming a reality.

Sattva Neelapu, MD, Professor, Department of Lymphoma and Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the role of off-the-shelf CAR natural killer (CAR NK) cell therapy in the treatment of B-cell malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai provides perspective on how oral therapies will impact the treatment landscape of myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai elaborates on the current approaches to treating elderly patients with myeloid malignancies.

Shyamala Navada, MD, MSCR, Associate Professor, Hematology and Medical Oncology, @MountSinaiNYC @IcahnMountSinai offers opinion on how the treatment of myelodysplastic syndromes (MDS) is changing, especially as a result of the clinical data presented at ASH 2019.

First time findings published in Nucleic Acids Research demonstrate the ability to differentiate exosomes from cancer cell subtypes from the same tumor type offering broad potential applications in biomarker discovery Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the publication of new data in Nucleic Acids Research, illustrating that use of the Company’s proprietary ADAPT Biotargeting Systemâ„¢ can lead to the identification of differences in protein expression patterns between exosomes from two related prostate cancer cell lines, vertebral cancer of the prostate (VCaP) and lymph node cancer of the prostate…

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, discusses if there is an association between minimal residual disease (MRD) and long-term survival outcomes in multiple myeloma (MM)

Nikhil Munshi, MD, Professor of Medicine, @HarvardHealth @harvardmed @DanaFarber Director of Basic and Correlative Science, tells us about the outcomes of the CARTITUDE-1 study investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma patients.

Pancreatic cancer has one of the worst survival rates among cancers. Patients can expect as low as a 9% chance to live for at least five years after being diagnosed. Going back in time to observe how cells with key gene mutations interact and become invasive would help researchers better understand how the cancer starts and identify it sooner. A pancreatic cancer “time machine” engineered by Purdue University researchers has revealed that the disease is even more unpredictable than previously thought: Cancer cells promote each other’s invasiveness when they grow together. The study, published in the journal Small, is just the beginning of…

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center @HackensackUMC explains how the treatment of myelodysplastic syndromes (MDS) is changing as a result of clinical data presented at ASH 2019.

James McCloskey, MD, Interim Chief, Division of Leukemia, John Theurer Cancer Center, Part of Hackensack University Medical Center, shares his impression of the Phase 3 ASCERTAIN study investigating cedazuridine and decitabine versus decitabine in myelodysplastic syndromes (MDS).

Longeveron LLC, a leading developer of adult stem cell technologies for aging-related and life-threatening conditions, announced today that it has completed enrollment in its Phase 2b Aging Frailty trial.  This double-blinded, randomized, placebo-controlled study is designed to evaluate the safety and efficacy of LMSCs in patients with mild to moderate frailty.     This 150 subject multicenter study is sponsored in part by a Small Business Innovation Research (SBIR) Grant from the National Institute of Aging (NIA), as part of the Geroscience initiative focused on preventing and treating age-related conditions, functional decline, and disability. “We are extremely pleased to achieve this…

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai discusses whether molecular analysis is appropriate and helpful in determining treatment approaches for myeloproliferative neoplasms.

John Mascarenhas, MD Associate Professor of Medicine, Myeloproliferative Disorders Program-Division of Hematology/Oncology @IcahnMountSinai tells us about his approach to the individualized management of myeloproliferative neoplasms.